EQ
- Equillium, Inc.
()
Overview
Company Summary
Equillium, Inc. is a biopharmaceutical company that focuses on developing novel therapies for immune and inflammatory disorders. The company primarily works on the modulation of the body's immune response to treat various diseases in multiple therapeutic areas.
Equillium's main area of interest is targeting the checkpoint blockade immunotherapy pathway, which plays a crucial role in regulating the immune system. By leveraging this pathway, the company aims to develop therapies that can address unmet medical needs in autoimmune and inflammatory diseases.
Equillium's lead product candidate is itolizumab, an antibody designed to selectively target the immunity checkpoint receptor CD6. CD6 is involved in regulating the activation and function of T cells, which are key players in immune responses. By targeting CD6, itolizumab has the potential to modulate the immune system and provide therapeutic benefits in autoimmune and inflammatory conditions.
The company is conducting clinical trials to evaluate itolizumab's efficacy and safety in various indications, including acute graft-versus-host disease (aGVHD), lupus nephritis, and uncontrolled asthma. Equillium's goal is to demonstrate the potential of itolizumab as a treatment option for these conditions, ultimately improving patient outcomes and quality of life.
In addition to itolizumab, Equillium is actively exploring other potential therapeutic candidates in immune-mediated disorders. The company's research and development efforts are driven by a deep understanding of the immune system and the identification of promising targets for intervention. Equillium aims to deliver innovative and transformative therapies that address the unmet needs of patients suffering from immune and inflammatory disorders.